Investor Centre
2021 Annual General Meeting
Read moreActinogen Webcast 27 April 2022
Actinogen hosted a webcast on 27 April 2022 to review the positive XanaMIA Part A trial topline results for Xanamem.
View webcast presentation slides
Watch webcastASX Announcements
Corporate Presentations
Analyst Reports
-
12 May 2022
Edison Healthcare Insight: May 2022
Analyst: Soo Romanoff
Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 9 May 2022This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report -
14 Apr 2022
Edison Healthcare Insight: April 2022
Analyst: Jonas Peculias
Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 11 April 2022This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report -
17 Mar 2022
Edison Healthcare Insight: March 2022
Analyst: Jonas Peculias
Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 14 March 2022This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report -
10 Feb 2022
Edison Healthcare Insight: February 2022
Analyst: Jonas Peculias
Refer to page 6 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 7 February 2022This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.
Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.
Continue to report
Frequently Asked Questions
The Company listed on the Australian Securities Exchange in 2007 as Actinogen Limited. In 2014, the Company acquired Corticrine from Edinburgh University, a company focused on the development of brain penetrant 11β-HSD1 enzyme inhibitors for the treatment of cognitive impairment. The lead drug in development by Corticrine was Xanamem. Corticrine received A$25m support from the Seeding Drug Discovery program of the Wellcome Trust and the University of Edinburgh and successfully completed a Phase 1 single ascending dose (SAD) study of UE2343 (Xanamem) in healthy human volunteers. Corticrine then became part of Actinogen Limited and the company subsequently rebranded to become Actinogen Medical in 2015.
Suite 901, Level 9, 109 Pitt Street, Sydney, NSW 2000
The share registry is managed by Automic Pty Ltd. To login and access your holding information, please go to: https://investor.automic.com.au
Shareholders can check their shareholdings by logging into the Automic investor portal https://investor.automic.com.au
If you have any queries in relation to your shareholding, please contact Automic by telephone on 1300 288 664 (within Australia) or +61 2 9698 5414 (international) or by email at hello@automicgroup.com.au.
All company shares are traded on the Australian Securities Exchange (ASX) and can be bought or sold through a licensed stockbroker. The process of buying or selling shares is explained on the ASX website; please go to
https://www.asx.com.au/products/shares/buying-selling-shares.htm
Non-Australian residents wishing to invest in ACW shares should contact a licensed stock broker which offers cross border transaction services with Australia. Alternatively, online trading platforms offer solutions for overseas investors to invest in international equities. Investors should note that ACW is only listed on the Australian Securities Exchange.
All annual reports are available on our website through this link.
Current share prices are available on the ASX website www.asx.com.au and can be searched using the Company’s ASX ticker symbol: ACW. A 20-minute delayed share price graph can also be found in our Investor Centre.
The ASX ticker code for the Company is ASX:ACW
The latest financial reports can be found in our Results Centre.
The Company’s end of financial year is the 30th of June
As a listed company Actinogen is required to hold its annual general meeting within five months of its financial year end. Accordingly, shareholders will be notified in the months of September or October, approximately 28 days in advance of when and where the AGM will be held. Typically, Actinogen holds its AGM towards the end of November.
The Company’s auditors are Ernst and Young
K&L Gates
Peter Webse
Email: pwebse@governancecorp.com.au
Our Corporate Governance Statement can be found on our website at: https://actinogen.com.au/investor-centre/#corporate-governance
This section includes downloadable PDFs of our Board and Committee Charters, the Constitution, Anti-Bribery and Corruption Policy, Code of Conduct, Continuous Disclosure Policy, Directors Skills Matrix, Diversity Policy, Performance Evaluation Practices, Procedures for Selection and Appointment of Directors, Remuneration Policy, Risk Management and Internal Compliance and Control, Securities Trading Policy, and Shareholders Communication Policy.
The Company does not currently have a dividend policy as the Company is not yet revenue generating. The Board reviews its growth strategy at regular intervals and assesses it against the Company’s working capital requirements and growth opportunities. Until the Company is generating returns, it is not expected to implement a dividend policy.
Corporate Governance
Find out moreInvestor Contacts
Actinogen Medical Ltd (ACN 086 778 476) is listed on the Australian Securities Exchange (ASX) with the code ACW.
Retail shareholder queries should be directed to Actinogen Medical’s share registrars, Automic Pty Ltd.
| Address: |
Level 5, 126 Phillip Street GPO Box 5193 |
| Phone: |
+61 1300 288 664 (within Australia) |
| Email: | |
| Web: |
